retinol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
retinol derivatives 2831 68-26-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vitamin A1
  • vitamin A
  • retinol
  • retinol (vit A)
Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.
  • Molecular weight: 286.46
  • Formula: C20H30O
  • CLOGP: 6.40
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 1
  • TPSA: 20.23
  • ALOGS: -4.58
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 TU O
50 TU P
800 U N

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.04 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 5.085 Moderate 0.70
caco2-efflux Caco-2 efflux ratio (BA/AB) 5.916 Moderate 0.70
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.164 10^-6 cm/s Moderate 0.70
dh-clint Dog hepatocyte intrinsic clearance 47.643 uL/min/10^6 cells Moderate 0.70
dppb Dog plasma protein binding (% unbound) 0.140 % Moderate 0.70
fcs-ppb Fetal calf serum protein binding (% unbound) 0.170 % Moderate 0.70
herg hERG pIC50 4.749 pIC50 Moderate 0.70
hh-clint Human hepatocyte intrinsic clearance 56.885 uL/min/10^6 cells Moderate 0.70
hlm-clint Human liver microsomal intrinsic clearance 35.892 uL/min/mg protein Moderate 0.70
hppb Human plasma protein binding (% unbound) 0.140 % Moderate 0.70
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K7,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,STK33,TEK,TGFBR1 25
kinase-selectivity-class AXL,BRAF,CDK4,GRK2,MAP2K6,STK33 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.297 Moderate 0.70
mh-clint Mouse hepatocyte intrinsic clearance 279.254 Moderate 0.70
mppb Mouse plasma protein binding (% unbound) 0.100 Moderate 0.70
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.480 Moderate 0.70
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.090 % Moderate 0.70
rh-clint Rat hepatocyte intrinsic clearance 160.325 uL/min/10^6 cells Moderate 0.70
rh-fuinc Rat hepatocyte fraction unbound in incubation 0.850 % Moderate 0.70
rppb Rat plasma protein binding (% unbound) 0.130 % Moderate 0.70
solubility-dd Solubility at pH 7.4 in DMSO 1.954 uM Moderate 0.70

Approvals:

DateAgencyCompanyOrphan
Feb. 20, 1953 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 101.83 10.08 57 75734 287789 90264867
Completed suicide 97.36 10.08 6 75785 145052 90407604
Gastrooesophageal reflux disease 95.29 10.08 331 75460 166006 90386650
Pneumonia aspiration 92.89 10.08 141 75650 40799 90511857
Injection site reaction 81.86 10.08 214 75577 91866 90460790
Onychomadesis 73.02 10.08 135 75656 45863 90506793
Onychomycosis 72.74 10.08 120 75671 37256 90515400
Drug ineffective 71.83 10.08 777 75014 1383521 89169135
Blood magnesium increased 68.52 10.08 40 75751 3368 90549288
Pleural thickening 67.63 10.08 39 75752 3209 90549447
Presbyacusis 64.61 10.08 37 75754 3005 90549651
Pleural fibrosis 61.40 10.08 38 75753 3558 90549098
Maternal exposure during pregnancy 58.81 10.08 134 75657 359929 90192727
Off label use 55.71 10.08 622 75169 1101630 89451026
Intentional overdose 50.01 10.08 9 75782 93825 90458831
Muscle spasms 44.81 10.08 362 75429 251521 90301135
Cyst 44.80 10.08 62 75729 16499 90536157
Underdose 44.42 10.08 122 75669 53895 90498761
Product dose omission issue 42.92 10.08 402 75389 291285 90261371
Deafness neurosensory 41.59 10.08 39 75752 6802 90545854
Diarrhoea 40.43 10.08 1049 74742 938141 89614515
Epigastric discomfort 40.09 10.08 40 75751 7528 90545128
Unevaluable event 39.40 10.08 118 75673 54730 90497926
Memory impairment 38.68 10.08 290 75501 196954 90355702
Full blood count decreased 38.45 10.08 80 75711 29609 90523047
Device expulsion 38.36 10.08 97 75694 40789 90511867
Epidermal necrosis 37.92 10.08 24 75767 2337 90550319
Coma 34.40 10.08 136 75655 72496 90480160
Fall 32.24 10.08 574 75217 481236 90071420
Drug interaction 31.93 10.08 121 75670 276332 90276324
Suicide attempt 31.16 10.08 12 75779 75387 90477269
Haemoglobin decreased 30.56 10.08 236 75555 161720 90390936
Nausea 30.08 10.08 1173 74618 1109143 89443513
COVID-19 29.89 10.08 60 75731 168783 90383873
Hepatic cirrhosis 28.80 10.08 117 75674 63136 90489520
Infective pulmonary exacerbation of cystic fibrosis 28.58 10.08 39 75752 10240 90542416
Hypoaesthesia 28.48 10.08 394 75397 313816 90238840
Contraindicated product administered 28.10 10.08 155 75636 319984 90232672
Therapy cessation 27.81 10.08 80 75711 36281 90516375
Walking aid user 27.04 10.08 78 75713 35428 90517228
Psoriasis 26.60 10.08 213 75578 147541 90405115
Exposure during pregnancy 26.47 10.08 106 75685 238304 90314352
Choanal stenosis 26.32 10.08 6 75785 27 90552629
Febrile neutropenia 25.76 10.08 59 75732 158290 90394366
Osteopenia 25.26 10.08 58 75733 22944 90529712
Hepatic necrosis 25.22 10.08 29 75762 6409 90546247
Dizziness 25.21 10.08 658 75133 588626 89964030
Somnolence 24.90 10.08 276 75515 208808 90343848
Asthma 24.83 10.08 111 75680 242049 90310607
Device dislocation 24.79 10.08 70 75721 31412 90521244
Blood potassium increased 24.67 10.08 54 75737 20695 90531961
Spinal fusion surgery 24.66 10.08 40 75751 12243 90540413
Prescribed underdose 24.63 10.08 126 75665 74893 90477763
Osteoarthritis 24.52 10.08 261 75530 195469 90357187
Neuropathy peripheral 24.41 10.08 197 75594 136773 90415883
Hand deformity 24.12 10.08 147 75644 296215 90256441
Drug-induced liver injury 23.84 10.08 143 75648 90175 90462481
Deep vein thrombosis 22.88 10.08 143 75648 91477 90461179
Flatulence 22.52 10.08 81 75710 41286 90511370
Anaphylactic reaction 22.45 10.08 24 75767 87500 90465156
Taste disorder 22.07 10.08 106 75685 61440 90491216
Bone cyst 21.47 10.08 17 75774 2361 90550295
Dry eye 20.94 10.08 100 75691 57831 90494825
Glossodynia 20.63 10.08 171 75620 321608 90231048
Illness 20.45 10.08 23 75768 81946 90470710
C-reactive protein abnormal 20.43 10.08 179 75612 127250 90425406
Intentional product misuse 20.39 10.08 27 75764 89577 90463079
Paraesthesia 20.33 10.08 308 75483 250018 90302638
Fatigue 20.25 10.08 1168 74623 1152855 89399801
Hepatic function abnormal 19.75 10.08 7 75784 46281 90506375
Hiatus hernia strangulated 19.65 10.08 8 75783 304 90552352
Thrombocytopenia 19.45 10.08 99 75692 208626 90344030
Oedema peripheral 18.93 10.08 312 75479 257603 90295053
Rash papular 18.79 10.08 48 75743 20307 90532349
Granulomatous liver disease 18.71 10.08 11 75780 938 90551718
Joint swelling 18.41 10.08 303 75488 502997 90049659
Wound infection 18.40 10.08 152 75639 106250 90446406
Feeling abnormal 18.22 10.08 217 75574 167018 90385638
Sleep disorder 18.20 10.08 249 75542 197781 90354875
Sleep disorder due to general medical condition, insomnia type 17.82 10.08 52 75739 128642 90424014
Hepatic encephalopathy 17.70 10.08 37 75754 13735 90538921
Acute kidney injury 17.61 10.08 177 75614 320210 90232446
Depressed level of consciousness 17.53 10.08 21 75770 72763 90479893
Gait inability 17.28 10.08 193 75598 146263 90406393
Multiple organ dysfunction syndrome 17.24 10.08 19 75772 68317 90484339
Weight decreased 17.03 10.08 427 75364 379483 90173173
Anaphylactic shock 16.92 10.08 3 75788 31614 90521042
Type 2 diabetes mellitus 16.86 10.08 251 75540 202993 90349663
Seronegative arthritis 16.83 10.08 43 75748 18191 90534465
Blepharospasm 16.74 10.08 91 75700 55354 90497302
Plasma cell myeloma 16.63 10.08 73 75718 40755 90511901
Osteochondritis 16.59 10.08 4 75787 24 90552632
Interstitial lung disease 16.41 10.08 24 75767 76381 90476275
Fluid retention 16.40 10.08 128 75663 87963 90464693
International normalised ratio decreased 16.39 10.08 20 75771 4704 90547952
Pelvic pain 16.07 10.08 38 75753 15319 90537337
Adverse reaction 16.02 10.08 58 75733 29654 90523002
Constipation 15.96 10.08 326 75465 280069 90272587
Aorta hypoplasia 15.89 10.08 6 75785 186 90552470
Abdominal distension 15.82 10.08 173 75618 130428 90422228
Drug eruption 15.72 10.08 5 75786 35402 90517254
Cardiac arrest 15.57 10.08 41 75750 104894 90447762
Agranulocytosis 15.44 10.08 5 75786 34997 90517659
Psoriatic arthropathy 15.22 10.08 272 75519 228063 90324593
Product use issue 15.08 10.08 190 75601 329729 90222927
Hepatocellular injury 14.96 10.08 3 75788 28955 90523701
Hypertension 14.95 10.08 281 75510 457251 90095405
Arthropathy 14.90 10.08 216 75575 366026 90186630
Cardiac failure 14.61 10.08 45 75746 109451 90443205
Pain in extremity 14.57 10.08 486 75305 450043 90102613
Osteosclerosis 14.52 10.08 18 75773 4302 90548354
Enterobacter infection 14.33 10.08 14 75777 2569 90550087
Cytokine release syndrome 14.24 10.08 3 75788 27970 90524686
Serotonin syndrome 14.12 10.08 7 75784 37880 90514776
Visual impairment 14.09 10.08 171 75620 132194 90420462
Drug intolerance 13.98 10.08 277 75514 447314 90105342
Skin lesion 13.86 10.08 65 75726 37300 90515356
Rheumatic fever 13.85 10.08 192 75599 152929 90399727
Hypervitaminosis A 13.65 10.08 3 75788 11 90552645
Lower respiratory tract infection 13.55 10.08 139 75652 250520 90302136
Oedema 13.49 10.08 239 75552 200056 90352600
Neutropenia 13.30 10.08 122 75669 224782 90327874
Drug ineffective for unapproved indication 13.29 10.08 22 75769 66622 90486034
Hepatic enzyme increased 13.23 10.08 217 75574 360519 90192137
Rhabdomyolysis 13.20 10.08 14 75777 51242 90501414
Eye swelling 13.09 10.08 54 75737 29332 90523324
Back injury 13.06 10.08 75 75716 46547 90506109
Altered state of consciousness 13.06 10.08 5 75786 31527 90521129
Tooth disorder 12.97 10.08 56 75735 31034 90521622
Respiratory arrest 12.65 10.08 6 75785 33305 90519351
Spondylitis 12.64 10.08 33 75758 14145 90538511
Therapy non-responder 12.64 10.08 65 75726 136639 90416017
Neutrophil hypersegmented morphology present 12.44 10.08 3 75788 18 90552638
Epilepsy 12.42 10.08 114 75677 82092 90470564
Anti-cyclic citrullinated peptide antibody positive 12.42 10.08 132 75659 236301 90316355
Diabetes mellitus 12.40 10.08 22 75769 64853 90487803
Vertebral lateral recess stenosis 12.38 10.08 6 75785 346 90552310
Hypersensitivity 12.28 10.08 288 75503 454389 90098267
Osteoarthropathy 12.13 10.08 6 75785 362 90552294
Ligamentum flavum hypertrophy 11.99 10.08 6 75785 371 90552285
Otitis media acute 11.97 10.08 9 75782 1158 90551498
Blood pressure systolic increased 11.88 10.08 19 75772 58326 90494330
Hip fracture 11.88 10.08 57 75734 33020 90519636
Electrocardiogram QT prolonged 11.78 10.08 27 75764 72429 90480227
Asthenia 11.69 10.08 552 75239 533199 90019457
Blood potassium decreased 11.61 10.08 74 75717 47653 90505003
Laboratory test abnormal 11.51 10.08 67 75724 41787 90510869
Duodenal ulcer perforation 11.44 10.08 124 75667 221164 90331492
Blister 11.22 10.08 148 75643 254850 90297806
Depression 11.22 10.08 330 75461 300271 90252385
Shock 11.21 10.08 5 75786 28773 90523883
Pneumonia 11.17 10.08 646 75145 637413 89915243
Leukopenia 11.03 10.08 45 75746 100665 90451991
Liver function test increased 11.02 10.08 114 75677 84741 90467915
Osteonecrosis of jaw 10.86 10.08 10 75781 39093 90513563
Body height decreased 10.85 10.08 28 75763 11921 90540735
Upper respiratory tract infection 10.84 10.08 159 75632 128159 90424497
Subacute sclerosing panencephalitis 10.75 10.08 3 75788 34 90552622
Tracheo-oesophageal fistula 10.72 10.08 7 75784 719 90551937
Angioedema 10.69 10.08 24 75767 64852 90487804
Bone hypertrophy 10.66 10.08 6 75785 471 90552185
Lymphopenia 10.58 10.08 3 75788 22878 90529778
Back disorder 10.57 10.08 46 75745 25585 90527071
Therapeutic response decreased 10.52 10.08 39 75752 89690 90462966
Product use in unapproved indication 10.52 10.08 208 75583 336028 90216628
Sedation 10.47 10.08 15 75776 48156 90504500
Cholestasis 10.42 10.08 9 75782 36290 90516366
Exostosis 10.33 10.08 78 75713 53056 90499600
Hypokalaemia 10.16 10.08 66 75725 131050 90421606
Pancytopenia 10.12 10.08 59 75732 120204 90432452
Intentional self-injury 10.09 10.08 6 75785 29328 90523328

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 122.39 11.89 151 28564 638184 41954436
Fatigue 65.00 11.89 508 28207 435133 42157487
Product use in unapproved indication 62.65 11.89 23 28692 184433 42408187
Drug abuse 45.24 11.89 8 28707 104763 42487857
Completed suicide 44.76 11.89 6 28709 96459 42496161
Plasma cell myeloma 43.65 11.89 98 28617 47480 42545140
Respiratory tract infection bacterial 41.76 11.89 22 28693 1887 42590733
Drug interaction 40.35 11.89 74 28641 266925 42325695
Laboratory test abnormal 39.55 11.89 62 28653 22916 42569704
White blood cell count decreased 38.62 11.89 162 28553 110234 42482386
Toxicity to various agents 37.83 11.89 60 28655 229076 42363544
Full blood count decreased 37.52 11.89 57 28658 20503 42572117
Product dose omission issue 35.61 11.89 201 28514 154164 42438456
Drug ineffective 35.12 11.89 265 28450 629932 41962688
Fall 35.08 11.89 274 28441 234246 42358374
Diarrhoea 34.13 11.89 466 28249 460383 42132237
Asthenia 33.54 11.89 312 28403 280481 42312139
Respiratory tract infection viral 32.32 11.89 23 28692 3383 42589237
Infective pulmonary exacerbation of cystic fibrosis 29.23 11.89 31 28684 7787 42584833
Sinusitis 26.48 11.89 81 28634 47211 42545409
Dizziness 25.38 11.89 268 28447 248986 42343634
Adverse drug reaction 24.70 11.89 68 28647 37366 42555254
General physical health deterioration 24.56 11.89 40 28675 151206 42441414
Haemoglobin decreased 24.52 11.89 163 28552 132308 42460312
Viral infection 23.69 11.89 49 28666 22434 42570186
Neuropathy peripheral 22.39 11.89 131 28584 101722 42490898
Influenza 22.32 11.89 92 28623 62083 42530537
Intentional product misuse 22.23 11.89 7 28708 61893 42530727
Muscle spasms 21.80 11.89 115 28600 85929 42506691
Interstitial lung disease 21.65 11.89 13 28702 78449 42514171
Peripheral swelling 21.09 11.89 118 28597 90152 42502468
Platelet count decreased 20.72 11.89 162 28553 138419 42454201
Febrile neutropenia 20.37 11.89 61 28654 185642 42406978
Dehydration 19.72 11.89 163 28552 141604 42451016
Psoriasis 19.11 11.89 74 28641 48530 42544090
Pneumonia 18.71 11.89 393 28322 421756 42170864
Flatulence 17.91 11.89 47 28668 25105 42567515
Hypervitaminosis A 17.90 11.89 4 28711 21 42592599
Treatment failure 17.81 11.89 10 28705 62614 42530006
Myelosuppression 17.65 11.89 3 28712 40458 42552162
Rash 17.61 11.89 273 28442 276681 42315939
Multiple organ dysfunction syndrome 17.36 11.89 24 28691 97011 42495609
Fibrin D dimer increased 17.29 11.89 19 28696 4966 42587654
Constipation 17.20 11.89 176 28539 162115 42430505
Hepatic function abnormal 16.54 11.89 7 28708 51560 42541060
Cardiac disorder 16.46 11.89 71 28644 48861 42543759
Overdose 16.02 11.89 29 28686 105235 42487385
Weight decreased 16.01 11.89 212 28503 207736 42384884
Foetal exposure during pregnancy 15.87 11.89 6 28709 47305 42545315
Memory impairment 15.48 11.89 71 28644 50151 42542469
Drug ineffective for unapproved indication 15.24 11.89 6 28709 46157 42546463
Coma 14.60 11.89 9 28706 53545 42539075
Small intestinal obstruction 14.38 11.89 34 28681 17027 42575593
Hypoaesthesia 13.86 11.89 89 28626 71374 42521246
Headache 13.73 11.89 232 28483 239137 42353483
Balance disorder 13.69 11.89 66 28649 47579 42545041
Feeling abnormal 13.59 11.89 87 28628 69699 42522921
Unevaluable event 13.31 11.89 52 28663 34236 42558384
Drug reaction with eosinophilia and systemic symptoms 13.04 11.89 6 28709 42069 42550551
Leukopenia 12.86 11.89 19 28696 74727 42517893
Seasonal allergy 12.85 11.89 21 28694 8034 42584586
Haematocrit decreased 12.79 11.89 52 28663 34856 42557764
Blood testosterone decreased 12.55 11.89 16 28699 4886 42587734
Hypersomnia 12.17 11.89 29 28686 14589 42578031
Influenza like illness 12.12 11.89 48 28667 31792 42560828
Drug resistance 12.07 11.89 4 28711 34244 42558376
Hospice care 12.00 11.89 21 28694 8492 42584128

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 139.80 9.93 97 83872 480458 110024872
Completed suicide 139.45 9.93 12 83957 242369 110262961
Off label use 112.70 9.93 674 83295 1499511 109005819
Drug abuse 104.21 9.93 8 83961 177403 110327927
Gastrooesophageal reflux disease 103.18 9.93 336 83633 179640 110325690
Injection site reaction 87.87 9.93 203 83766 88867 110416463
Onychomadesis 87.36 9.93 138 83831 45525 110459805
Onychomycosis 81.52 9.93 122 83847 38409 110466921
Drug interaction 76.67 9.93 166 83803 500017 110005313
Drug ineffective 69.89 9.93 779 83190 1519761 108985569
Intentional overdose 67.57 9.93 10 83959 132491 110372839
Presbyacusis 59.42 9.93 33 83936 2786 110502544
Pleural thickening 58.84 9.93 35 83934 3364 110501966
Infective pulmonary exacerbation of cystic fibrosis 58.69 9.93 64 83905 14707 110490623
Blood magnesium increased 57.55 9.93 36 83933 3787 110501543
Myelosuppression 56.12 9.93 4 83965 94336 110410994
Device expulsion 54.51 9.93 90 83879 30801 110474529
Pneumonia aspiration 54.25 9.93 160 83809 81073 110424257
Fall 51.40 9.93 691 83278 602791 109902539
Pleural fibrosis 48.88 9.93 34 83935 4274 110501056
Product dose omission issue 48.83 9.93 414 83555 321368 110183962
Intentional product misuse 46.99 9.93 21 83948 132883 110372447
Muscle spasms 46.58 9.93 366 83603 277791 110227539
Haemoglobin decreased 44.84 9.93 333 83636 248394 110256936
Dizziness 44.20 9.93 760 83209 697433 109807897
Underdose 43.22 9.93 126 83843 63428 110441902
Febrile neutropenia 43.02 9.93 112 83857 316655 110188675
Fatigue 39.66 9.93 1205 82764 1214753 109290577
Epigastric discomfort 37.47 9.93 40 83929 8975 110496355
Asthma 35.92 9.93 86 83883 250205 110255125
Plasma cell myeloma 35.58 9.93 117 83852 62819 110442511
Cyst 34.56 9.93 52 83917 16444 110488886
Respiratory tract infection bacterial 34.49 9.93 22 83947 2394 110502936
Epidermal necrosis 34.44 9.93 24 83945 3026 110502304
Interstitial lung disease 34.38 9.93 33 83936 139301 110366029
Diarrhoea 33.91 9.93 1117 82852 1138388 109366942
COVID-19 33.76 9.93 86 83883 244974 110260356
Multiple organ dysfunction syndrome 32.92 9.93 40 83929 151670 110353660
Full blood count decreased 32.57 9.93 74 83895 32025 110473305
Suicide attempt 32.57 9.93 19 83950 103375 110401955
Memory impairment 32.32 9.93 258 83711 196686 110308644
Nausea 32.21 9.93 1193 82776 1234497 109270833
Hepatic function abnormal 31.73 9.93 14 83955 89281 110416049
Therapy cessation 31.53 9.93 90 83879 44767 110460563
Fluid retention 31.09 9.93 148 83821 94159 110411171
Asthenia 30.50 9.93 711 83258 688288 109817042
Deafness neurosensory 30.34 9.93 37 83932 9582 110495748
C-reactive protein abnormal 29.54 9.93 184 83785 129511 110375819
Depressed level of consciousness 28.40 9.93 26 83943 112252 110393078
Osteopenia 28.09 9.93 56 83913 22153 110483177
Hypervitaminosis A 27.63 9.93 7 83962 59 110505271
Dehydration 27.54 9.93 329 83640 279182 110226148
Deep vein thrombosis 27.34 9.93 191 83778 139696 110365634
Hypoaesthesia 27.18 9.93 361 83608 313862 110191468
Drug resistance 27.08 9.93 5 83964 56369 110448961
Device dislocation 26.70 9.93 68 83901 31636 110473694
Acute kidney injury 26.51 9.93 332 83637 635098 109870232
Eosinophilia 26.05 9.93 6 83963 57930 110447400
Drug ineffective for unapproved indication 25.79 9.93 24 83945 102814 110402516
Rheumatic fever 24.92 9.93 169 83800 122410 110382920
Sleep disorder 24.25 9.93 244 83725 198400 110306930
Product use in unapproved indication 24.21 9.93 220 83749 447157 110058173
Unevaluable event 24.11 9.93 99 83870 59128 110446202
Taste disorder 24.07 9.93 106 83863 65281 110440049
Cytomegalovirus infection 23.77 9.93 6 83963 54438 110450892
Therapeutic response decreased 23.64 9.93 23 83946 96476 110408854
Psoriatic arthropathy 22.74 9.93 239 83730 196522 110308808
Flatulence 21.89 9.93 88 83881 52061 110453269
Blepharospasm 21.79 9.93 91 83878 54760 110450570
Blood potassium increased 21.73 9.93 65 83904 33184 110472146
Cholestasis 21.57 9.93 11 83958 64507 110440823
Paraesthesia 21.21 9.93 311 83658 276210 110229120
Rhabdomyolysis 20.97 9.93 37 83932 120364 110384966
Respiratory tract infection viral 20.84 9.93 24 83945 5854 110499476
Cardiac failure 20.68 9.93 73 83896 187553 110317777
Hiatus hernia strangulated 20.39 9.93 8 83961 304 110505026
Hospice care 20.23 9.93 35 83934 12438 110492892
Drug eruption 19.73 9.93 8 83961 53651 110451679
Diabetes mellitus 19.71 9.93 28 83941 99353 110405977
Illness 19.65 9.93 20 83949 82151 110423179
Leukopenia 19.13 9.93 54 83915 148737 110356593
Anaphylactic reaction 19.12 9.93 36 83933 114264 110391066
Hypervolaemia 18.83 9.93 81 83888 49379 110455951
Dry eye 18.71 9.93 88 83881 55705 110449625
Osteosclerosis 18.70 9.93 20 83949 4495 110500835
Hip fracture 18.67 9.93 64 83905 35087 110470243
Therapy partial responder 18.43 9.93 3 83966 37058 110468272
Lymphopenia 18.38 9.93 4 83965 40166 110465164
Small intestinal obstruction 18.31 9.93 60 83909 32153 110473177
Septic shock 18.24 9.93 60 83909 157468 110347862
Multiple sclerosis relapse 18.15 9.93 81 83888 50159 110455171
Pneumocystis jirovecii pneumonia 18.10 9.93 5 83964 42730 110462600
Feeling abnormal 17.92 9.93 213 83756 180498 110324832
Hepatic necrosis 17.63 9.93 29 83940 9893 110495437
Pelvic pain 17.58 9.93 38 83931 15904 110489426
Hypertension 17.53 9.93 277 83692 509807 109995523
Neutropenia 17.43 9.93 191 83778 374429 110130901
Serotonin syndrome 17.08 9.93 12 83957 59141 110446189
Anaphylactic shock 16.92 9.93 9 83960 51537 110453793
Back injury 16.81 9.93 76 83893 47323 110458007
Back disorder 16.72 9.93 44 83925 20878 110484452
Adverse reaction 16.71 9.93 55 83914 29539 110475791
Shock 16.66 9.93 10 83959 53578 110451752
Sedation 16.62 9.93 17 83952 69666 110435664
Cardio-respiratory arrest 16.45 9.93 40 83929 115796 110389534
Depression 16.40 9.93 335 83634 317000 110188330
Altered state of consciousness 16.24 9.93 12 83957 57614 110447716
Accidental exposure to product 16.02 9.93 9 83960 49999 110455331
Neurotoxicity 16.00 9.93 6 83963 42201 110463129
Hospitalisation 15.95 9.93 172 83797 142321 110363009
Cardiac arrest 15.92 9.93 86 83883 196667 110308663
Abdominal distension 15.89 9.93 203 83766 174900 110330430
Osteochondritis 15.86 9.93 4 83965 33 110505297
General physical health deterioration 15.62 9.93 228 83741 425067 110080263
Osteoarthritis 15.44 9.93 209 83760 182414 110322916
Drug reaction with eosinophilia and systemic symptoms 15.44 9.93 24 83945 82071 110423259
Hepatic cirrhosis 15.43 9.93 96 83873 67530 110437800
Influenza like illness 15.14 9.93 117 83852 88295 110417035
Blood potassium decreased 15.08 9.93 81 83888 54033 110451297
Bone cyst 15.00 9.93 16 83953 3587 110501743
Blood pressure systolic increased 14.91 9.93 25 83944 82966 110422364
Cardiogenic shock 14.83 9.93 13 83956 57325 110448005
Oedema peripheral 14.76 9.93 340 83629 328320 110177010
Somnolence 14.71 9.93 312 83657 297137 110208193
Hepatic encephalopathy 14.62 9.93 51 83918 28205 110477125
Weight decreased 14.40 9.93 461 83508 467596 110037734
Migraine 14.33 9.93 196 83773 171456 110333874
Type 2 diabetes mellitus 14.24 9.93 201 83768 177031 110328299
Neutropenic sepsis 14.19 9.93 3 83966 30743 110474587
Rheumatoid arthritis 14.09 9.93 312 83657 299301 110206029
Gait inability 14.07 9.93 162 83807 136214 110369116
Neoplasm progression 14.04 9.93 17 83952 64578 110440752
Decreased appetite 13.95 9.93 466 83503 475380 110029950
Haematocrit decreased 13.94 9.93 92 83877 66025 110439305
Mental status changes 13.75 9.93 102 83867 76020 110429310
Impaired quality of life 13.71 9.93 3 83966 30014 110475316
Agranulocytosis 13.70 9.93 16 83953 61744 110443586
Hepatocellular injury 13.69 9.93 11 83958 50631 110454699
Injection site erythema 13.65 9.93 120 83849 94056 110411274
Vitamin A decreased 13.59 9.93 5 83964 159 110505171
Oedema 13.38 9.93 229 83740 209747 110295583
Labelled drug-drug interaction medication error 13.24 9.93 3 83966 29299 110476031
Angioedema 13.22 9.93 35 83934 98465 110406865
Finger deformity 13.22 9.93 55 83914 33037 110472293
Viral infection 13.12 9.93 77 83892 53062 110452268
Polyneuropathy 13.09 9.93 4 83965 32008 110473322
Injury 13.05 9.93 198 83771 177067 110328263
Vertebral lateral recess stenosis 12.94 9.93 6 83963 346 110504984
Dyspnoea exertional 12.78 9.93 128 83841 103932 110401398
Ligamentum flavum hypertrophy 12.57 9.93 6 83963 369 110504961
Osteoarthropathy 12.51 9.93 6 83963 373 110504957
Eye swelling 12.48 9.93 54 83915 32994 110472336
Thrombocytopenia 12.47 9.93 188 83781 348697 110156633
Lactic acidosis 12.44 9.93 33 83936 92778 110412552
Dyspepsia 12.44 9.93 209 83760 190756 110314574
Dyspnoea 12.39 9.93 988 82981 1105884 109399446
Granulomatous liver disease 12.38 9.93 10 83959 1574 110503756
Electrocardiogram QT prolonged 12.27 9.93 42 83927 108918 110396412
Maternal exposure during pregnancy 12.23 9.93 129 83840 254754 110250576
Coma 12.15 9.93 140 83829 117729 110387601
Pulmonary arterial hypertension 12.14 9.93 53 83916 32515 110472815
Tubulointerstitial nephritis 12.10 9.93 14 83955 54270 110451060
Toxic skin eruption 12.07 9.93 3 83966 27512 110477818
Circulatory collapse 12.05 9.93 9 83960 42984 110462346
Cardiac pacemaker insertion 11.99 9.93 19 83950 6282 110499048
Respiratory arrest 11.99 9.93 16 83953 58283 110447047
Complication associated with device 11.96 9.93 38 83931 20035 110485295
Mucosal inflammation 11.56 9.93 36 83933 96105 110409225
Cystic fibrosis 11.49 9.93 16 83953 4715 110500615
Vascular device infection 11.48 9.93 33 83936 16479 110488851
Hypogeusia 11.46 9.93 11 83958 2176 110503154
Respiratory depression 11.40 9.93 5 83964 31996 110473334
Pain in extremity 11.36 9.93 465 83504 486653 110018677
Overdose 11.35 9.93 118 83851 233676 110271654
Neutrophil hypersegmented morphology present 11.29 9.93 3 83966 31 110505299
Poisoning 11.26 9.93 4 83965 29101 110476229
Ventricular fibrillation 11.13 9.93 9 83960 41304 110464026
Osteonecrosis of jaw 11.13 9.93 12 83957 48005 110457325
Dysgeusia 11.10 9.93 91 83878 69894 110435436
Hypokalaemia 11.08 9.93 87 83882 182361 110322969
Dystonia 10.97 9.93 3 83966 25802 110479528
Product label confusion 10.94 9.93 40 83929 22637 110482693
Accidental overdose 10.89 9.93 14 83955 51820 110453510
Metabolic acidosis 10.86 9.93 39 83930 99705 110405625
Product complaint 10.77 9.93 29 83940 13943 110491387
Malignant neoplasm progression 10.71 9.93 83 83886 174484 110330846
International normalised ratio decreased 10.69 9.93 21 83948 8215 110497115
Hyperkalaemia 10.63 9.93 60 83909 135736 110369594
Pulmonary hypertension 10.55 9.93 75 83894 55145 110450185
Prescribed underdose 10.48 9.93 85 83884 65089 110440241
Blood pressure systolic abnormal 10.35 9.93 3 83966 24847 110480483
Otitis media acute 10.33 9.93 9 83960 1573 110503757
Fibrin D dimer increased 10.33 9.93 23 83946 9822 110495508
Epilepsy 10.32 9.93 119 83850 100090 110405240
Intentional self-injury 10.28 9.93 8 83961 37421 110467909
Breast cancer 10.27 9.93 57 83912 38485 110466845
Rash maculo-papular 10.25 9.93 26 83943 74196 110431134
Headache 10.25 9.93 790 83179 881587 109623743
Neuropathy peripheral 10.18 9.93 192 83777 179085 110326245
COVID-19 pneumonia 10.13 9.93 8 83961 37135 110468195
Musculoskeletal pain 10.05 9.93 195 83774 182828 110322502
Aplastic anaemia 10.01 9.93 3 83966 24305 110481025
Laryngeal pain 10.00 9.93 17 83952 5958 110499372
Bradycardia 9.99 9.93 73 83896 155444 110349886

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A11CA01 ALIMENTARY TRACT AND METABOLISM
VITAMINS
VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
Vitamin A, plain
ATC D10AD02 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Retinoids for topical use in acne
ATC R01AX02 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Other nasal preparations
ATC S01XA02 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
FDA CS M0022788 Vitamin A
MeSH PA D014815 Vitamins
MeSH PA D018977 Micronutrients
FDA EPC N0000175950 Vitamin A
CHEBI has role CHEBI:24020 fat-soluble vitamin (role)
CHEBI has role CHEBI:25212 metabolite
CHEBI has role CHEBI:77746 human metabolite

Related Drugs by ATC class:

A11CA Vitamin A, plain 1 drug
betacarotene
D10AD Retinoids for topical use in acne 5 drugs
adapaleneisotretinoinmotretinidetretinointrifarotene
R01AX Other nasal preparations 6 drugs
framycetinhexamidinehyaluronic acidipratropiummupirocinritiometan
S01XA Other ophthalmologicals 24 drugs
acetylcysteinealteplasealumascorbic acidavacincaptad pegolcenegerminciclosporindexpanthenoldiquafosolethylmorphineguaiazulenheparin show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vitamin A deficiency indication 72000004
Vitamin deficiency indication 85670002
Mineral deficiency indication 111379007
Prevention of dental caries indication 426482000
Mineral Deficiency Prevention indication
Vitamin Deficiency Prevention indication
Diaper rash off-label use 91487003
Abetalipoproteinemia off-label use 190787008 DOID:1386
Skin irritation off-label use 367466007
Peptic ulcer contraindication 13200003 DOID:750
Primary hyperoxaluria contraindication 17901006 DOID:2977
Hyperphosphatemia contraindication 20165001 DOID:0050459
Gastroenteritis contraindication 25374005 DOID:2326
Hypervitaminosis D contraindication 27712000 DOID:9971
Sarcoidosis contraindication 31541009 DOID:11335
Hemosiderosis contraindication 39011001 DOID:12119
Hemolytic anemia contraindication 61261009 DOID:583
Hypervitaminosis A contraindication 64559002 DOID:9972
Ulcerative colitis contraindication 64766004 DOID:8577
Hypercalcemia contraindication 66931009 DOID:12678
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Anemia due to enzyme deficiency contraindication 111577008
Hb SS disease contraindication 127040003 DOID:10923
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Arteriosclerosis obliterans contraindication 361133006 DOID:5160
Diverticular disease contraindication 397881000
Hemochromatosis contraindication 399187006 DOID:2352
Repeated Blood Transfusions contraindication
Malabsorption States contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.62 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL MULTIPLE VITAMINS INJECTION PEDIATRIC APOTEX A210671 April 21, 2026 RX INJECTABLE INTRAVENOUS Dec. 21, 2026 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
11-cis retinol dehydrogenase Enzyme WOMBAT-PK
Retinol dehydrogenase 12 Enzyme WOMBAT-PK
Retinol dehydrogenase 13 Enzyme WOMBAT-PK
Retinol-binding protein 3 Surface antigen WOMBAT-PK
Retinol-binding protein 5 Cytosolic other WOMBAT-PK
Retinoid-binding protein 7 Cytosolic other WOMBAT-PK
Retinol-binding protein 4 Secreted Kd 6.74 CHEMBL
Retinol-binding protein 2 Cytosolic other WOMBAT-PK
Retinal dehydrogenase 2 Enzyme WOMBAT-PK
Retinal dehydrogenase 1 Enzyme WOMBAT-PK
Retinaldehyde-binding protein 1 Transporter WOMBAT-PK
Retinol-binding protein 1 Cytosolic other WOMBAT-PK
Amyloid beta A4 protein Membrane other IC50 6.75 CHEMBL
Nuclear receptor subfamily 2 group C member 2 Nuclear other AGONIST EC50 4.71 IUPHAR
Alpha-synuclein Transporter IC50 6.72 CHEMBL
Beta-lactoglobulin Secreted Kd 7.44 CHEMBL

External reference:

IDSource
4021164 VUID
N0000148615 NUI
D06543 KEGG_DRUG
11103-57-4 SECONDARY_CAS_RN
4017648 VANDF
4021164 VANDF
4021715 VANDF
C0042839 UMLSCUI
CHEBI:45479 CHEBI
RTL PDB_CHEM_ID
CHEMBL986 ChEMBL_ID
DB00162 DRUGBANK_ID
D014801 MESH_DESCRIPTOR_UI
445354 PUBCHEM_CID
4053 IUPHAR_LIGAND_ID
2243 INN_ID
G2SH0XKK91 UNII
11246 RXNORM
232172 MMSL
5678 MMSL
975 MMSL
d00402 MMSL
001000 NDDF
82156005 SNOMEDCT_US
82622003 SNOMEDCT_US
G2SH0XKK91 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VitafolOne HUMAN PRESCRIPTION DRUG LABEL 16 0642-0070 CAPSULE, GELATIN COATED 330 ug ORAL unapproved drug other 14 sections
Vitafol OBCaplet HUMAN PRESCRIPTION DRUG LABEL 15 0642-0079 TABLET 2700 [iU] ORAL unapproved drug other 14 sections
Vitafol Plus HUMAN PRESCRIPTION DRUG LABEL 17 0642-0092 CAPSULE, LIQUID FILLED 1100 [iU] ORAL UNAPPROVED DRUG OTHER 13 sections
Strovite OneCaplets HUMAN PRESCRIPTION DRUG LABEL 20 0642-0207 TABLET 900 ug ORAL unapproved drug other 14 sections
Reaphirm Plant Source DHA HUMAN PRESCRIPTION DRUG LABEL 16 0642-3010 CAPSULE, GELATIN COATED 1100 [iU] ORAL unapproved drug other 7 sections
O-Cal Prenatal Vitamin HUMAN PRESCRIPTION DRUG LABEL 16 0813-0202 TABLET 2500 [iU] ORAL UNAPPROVED DRUG OTHER 6 sections
Budpak Vitamin A and D HUMAN OTC DRUG LABEL 2 27293-036 CREAM 181.80 [iU] TOPICAL OTC monograph not final 11 sections
Multivitamin with fluoride HUMAN PRESCRIPTION DRUG LABEL 11 50090-0356 TABLET, CHEWABLE 2500 [iU] ORAL UNAPPROVED DRUG OTHER 8 sections
Multivitamin with fluoride HUMAN PRESCRIPTION DRUG LABEL 11 50090-0435 TABLET, CHEWABLE 2500 [iU] ORAL UNAPPROVED DRUG OTHER 8 sections
Multivitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 12 50090-4475 TABLET, CHEWABLE 750 ug ORAL unapproved drug other 10 sections
Multi Vitamin and Mineralvitamin HUMAN OTC DRUG LABEL 11 51220-2001 TABLET, CHEWABLE 3.50 mg ORAL unapproved drug other 8 sections
Vitamin A and D HUMAN OTC DRUG LABEL 2 52000-026 CREAM 181.80 [iU] TOPICAL OTC Monograph Drug 11 sections
Kimchi Vitaminchewable multivitamin HUMAN OTC DRUG LABEL 11 52102-1001 TABLET, CHEWABLE 0.68 mg ORAL unapproved drug other 2 sections
Multi-Vitamin Fluoride Drops HUMAN PRESCRIPTION DRUG LABEL 10 52959-593 SOLUTION 1500 [iU] ORAL Unapproved drug other 11 sections
Multivitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 11 58657-163 TABLET, CHEWABLE 2500 [iU] ORAL unapproved drug other 10 sections
Multivitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 11 58657-163 TABLET, CHEWABLE 2500 [iU] ORAL unapproved drug other 10 sections
Multivitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 11 58657-164 TABLET, CHEWABLE 2500 [iU] ORAL unapproved drug other 10 sections
Multivitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 11 58657-164 TABLET, CHEWABLE 2500 [iU] ORAL unapproved drug other 10 sections
Multivitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 11 58657-165 TABLET, CHEWABLE 2500 [iU] ORAL unapproved drug other 10 sections
Multivitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 11 58657-165 TABLET, CHEWABLE 2500 [iU] ORAL unapproved drug other 10 sections
M-Natal Plus HUMAN PRESCRIPTION DRUG LABEL 14 58657-170 TABLET 4000 [iU] ORAL unapproved drug other 7 sections
M-Natal Plus HUMAN PRESCRIPTION DRUG LABEL 14 58657-170 TABLET 4000 [iU] ORAL unapproved drug other 7 sections
Tri-Vite Drops with Fluoride HUMAN PRESCRIPTION DRUG LABEL 4 58657-323 SOLUTION 1500 [iU] ORAL unapproved drug other 9 sections
Tri-Vite Drops with Fluoride HUMAN PRESCRIPTION DRUG LABEL 4 58657-323 SOLUTION 1500 [iU] ORAL unapproved drug other 9 sections
Tri-Vite Drops with Fluoride HUMAN PRESCRIPTION DRUG LABEL 4 58657-324 SOLUTION 1500 [iU] ORAL unapproved drug other 9 sections
Tri-Vite Drops with Fluoride HUMAN PRESCRIPTION DRUG LABEL 4 58657-324 SOLUTION 1500 [iU] ORAL unapproved drug other 9 sections
Flotrex HUMAN PRESCRIPTION DRUG LABEL 12 59088-015 TABLET, CHEWABLE 750 ug ORAL unapproved drug other 11 sections
Flotrex HUMAN PRESCRIPTION DRUG LABEL 12 59088-017 TABLET, CHEWABLE 750 ug ORAL unapproved drug other 11 sections
Multivitamin HUMAN PRESCRIPTION DRUG LABEL 11 59088-018 TABLET, CHEWABLE 750 ug ORAL unapproved drug other 11 sections
Flotrex HUMAN PRESCRIPTION DRUG LABEL 12 59088-020 TABLET, CHEWABLE 750 ug ORAL unapproved drug other 11 sections